Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-04-17
2007-04-17
Chism, B. Dell (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600
Reexamination Certificate
active
11007155
ABSTRACT:
The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.
REFERENCES:
patent: 4153689 (1979-05-01), Hirai et al.
patent: 5474978 (1995-12-01), Bakaysa et al.
patent: 5506203 (1996-04-01), Bäckström et al.
patent: 5948751 (1999-09-01), Kimer et al.
patent: 6211144 (2001-04-01), Havelund
patent: 6310038 (2001-10-01), Havelund
patent: 6908897 (2005-06-01), Brandenburg et al.
patent: 2002/0198140 (2002-12-01), Havelund
patent: 0 166 529 (1986-01-01), None
patent: 0 200 383 (1986-12-01), None
patent: 0 200 383 (1986-12-01), None
patent: 0 214 826 (1987-03-01), None
patent: 0 375 437 (1990-06-01), None
patent: 0 419 504 (1991-04-01), None
patent: 0 678 522 (1995-10-01), None
patent: WO 92/00321 (1992-01-01), None
patent: WO 98/42749 (1998-10-01), None
patent: WO 98/56406 (1998-12-01), None
patent: WO 00/74736 (2000-12-01), None
Hinds et al., Bioconjugate Chem. 2000, vol. 11, pp. 195-201.
W.D. Lougheed et al., “Physical Stability of Insulin Formulations,” Diabetes, 32: 424-32 (1983).
H. Thurow and K. Geisen, “Stabilisation of dissolved proteins against denaturation at hydrophobic interfaces,” Diabetologia, 27; 212-18 (1984).
J. Brange and L. Langkjeer, “Chemical stability of insulin 3. Influence of excipients, formulation, and pH,” Acta Pharma. Nord. 4(3):149-58 (1992).
D.L. Bakaysa et al., “Physicochemical basis for the rapid time-action of LysB28and ProB29-insulin: Dissociation of a protein-ligand complex,” Protein Science 5:2521-31 (1996).
J. Brange et al., “Monometric insulins and their experimental and clinical implications,” Diabetes Care 13(9):923-45 (1990).
J. Brange et al., “Neutral insulin solutions physically stabilized by addition of Zn2+,” Diabetic Medicine 3:532-6 (1986).
The Diabetes Control and Complications Trial Research Group “The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-term Complications in Insulin-dependent Diabetes Mellitus,” New England Journal of Medicine, 329(14):977-86 (1993).
Chism B. Dell
Finnegan Henderson Farabow Garrett & Dunner LLP
Sanofi-Aventis Deutschland Gmb
LandOfFree
Zinc-free and low-zinc insulin preparations having improved... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Zinc-free and low-zinc insulin preparations having improved..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Zinc-free and low-zinc insulin preparations having improved... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3746953